Rare disease

Rare disease scientific communications

Publications • Congress strategy • Digital media • Medical affairs

Eastmond Medicomm supports Medical Affairs teams in rare and orphan disease programmes to develop clear, publication-ready scientific narratives across abstracts, posters, manuscripts, congress content, symposia and digital media.

We offer senior-led medical communications expertise for complex datasets, specialist indications and global communication programmes.

Discuss an upcoming project.

What we do

Scientific communications support for rare disease programmes

Eastmond Medicomm works with pharmaceutical and biotechnology companies to deliver high-quality scientific communications across development and commercial lifecycle programmes.
Typical areas of support include:

  • Publication strategy and manuscript development
  • Abstract and poster development for major congresses
  • Scientific narrative development for complex datasets
  • Symposium and scientific meeting content
  • Medical education programmes and advisory boards.

Our work is designed to help Medical Affairs teams translate complex clinical data into clear, credible scientific communications.

Rare disease expertise

Specialist experience in rare and orphan diseases

Rare disease programmes present unique communications challenges.

Small datasets, highly specialised audiences and complex regulatory environments require careful narrative development and publication planning.

Eastmond Medicomm has extensive experience supporting rare disease and specialist therapy programmes, including recent work in neurology, immunology and metabolic disease.

Our focus is on ensuring that important scientific findings are communicated clearly, credibly and effectively to the clinical community.

Our model

A senior-led boutique model

Eastmond Medicomm operates as a specialist boutique agency.

Each project is led by experienced senior medical communications professionals and delivered through a trusted network of director-level associates.

This model allows us to assemble the right expertise for each programme while maintaining the quality and strategic oversight expected from experienced medical communications leadership.

Clients benefit from:

  • Direct access to senior expertise
  • Flexible project teams tailored to programme needs
  • High-quality delivery without the complexity of large agency structures.

Selected experience

Eastmond Medicomm has supported global pharmaceutical and biotechnology companies across a wide range of scientific communications activities, including:

  • Rare disease publication programmes
  • Congress abstract and poster development
  • Manuscript development and journal submission
  • International scientific meetings and symposia
  • Medical education initiatives for specialist therapy areas

Recent collaborations include global pharmaceutical companies and emerging rare disease biotechnology organisations.

Informational videos

Challenge: “Can you make a risk-management video for a loco-regional regulator?” Response: Eastmond Medicomm combined existing client assets with stock graphics and local branding guidelines to produce an 8-minute RMP video. A well-known actor was engaged for the voiceover, and the video was cut such that key information points appeared in time with the script …

NEJM

Challenge: “Can you get us into NEJM?” Response: Yes and no. The New England Journal of Medicine is the stone-like pinnacle of medical publishing upon which careers have been made and hopes have been dashed. Over 13 years of operation, we have submitted something like eight or so papers to NEJM. Only one of them …